Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

13

Revenue 2017

Bristol-Myers Squibb

The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of Bristol-Myers Squibb's 2013 sales performance.

Bristol-Myers Squibb

Roche pulls EU Tecentriq/Avastin filing in kidney cancer

Roche pulls EU Tecentriq/Avastin filing in kidney cancer

Bristol-Myers Squibb’s combination of PD-1 inhibitor Opdivo (nivolumab) and CTLA4 inhibitor Yervoy (ipilimumab) had been turned down by the CHMP earlier this year on the grounds that adding

AZ drug matched to cancer mutation passes phase 2 test

AZ drug matched to cancer mutation passes phase 2 test The first approvals for type-agnostic therapies have already been granted, with Merck/MSD’s Keytruda (pembrolizumab( and Bristol-Myers Squibb’s Opdivo (nivolumab) – both PD-1 checkpoint inhibitors – greenlighted for

FDA green lights BMS’ multiple myeloma combo

FDA green lights BMS’ multiple myeloma combo Bristol-Myers Squibb and AbbVie have gained a rapid FDA approval to broaden the use of multiple myeloma treatment Empliciti as part of new combined treatment regimen. ... tackle this relentless cancer, ”said Joseph Eid, senior vice president and head

US pricing plan slammed for imposing “foreign price controls”

US pricing plan slammed for imposing “foreign price controls” Analysts suggest the companies most affected by this would be Regeneron, Amgen, Roche, Johnson &Johnson and Bristol-Myers Squibb, as they have the largest exposure to Medicare Part B.

Result pages: 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 ()

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
mXm Medical Communications

mXm Medical Communications meets the needs of pharmaceutical marketers and medics who require a highly experienced, bespoke service from their...

Latest intelligence

Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...
Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...

Infographics